ADC Therapeutics S.A. (NYSE: ADCT)

https://www.adctherapeutics.com

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. *

	Start	2012-03-26 established pred
	Group	ADC Therapeutics (Group)
	Predecessor	ADC Therapeutics S.à.r.l. (ADCT)
	Industry	antibody-drug conjugates (ADC) technology
	Industry 2	cancer drug
	Person	Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co)
	Person 2	Gilman, David (ADC Therapeutics 202206– Chief Business + Strategy Officer before ClearView Healthcare Partners)

	Region	Epalinges VD
	Country	Switzerland
	Street	3B Route de la Corniche
	City	1066 Epalinges VD
	Tel	+41-21-653-0200
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2021-12-31)
	Currency	USD
	Annual sales	33,917,000 (revenue, total, consolidated (2021) 2021-12-31)
	Profit	-230,026,000 (2021-12-31)
	Cash	466,544,000 (2021-12-31)

		* Document for ï¿½About Sectionï¿½: ADC Therapeutics S.A.. (6/13/22). "Press Release: ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer". Lausanne.

		Record changed: 2022-06-13